| scholarly article | Q13442814 |
| P50 | author | Scott Gettinger | Q66809423 |
| Hossein Borghaei | Q91136109 | ||
| P2093 | author name string | Frances A Shepherd | |
| Scott Antonia | |||
| David E Gerber | |||
| Yun Shen | |||
| Rosalyn A Juergens | |||
| Neal Ready | |||
| Matthew D Hellmann | |||
| Scott A Laurie | |||
| Jonathan W Goldman | |||
| Naiyer A Rizvi | |||
| Laura Q Chow | |||
| Julie Brahmer | |||
| Christopher T Harbison | |||
| Faith E Nathan | |||
| P2860 | cites work | Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations | Q27021203 |
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. | Q33345025 | ||
| In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates | Q34421845 | ||
| Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations | Q34449385 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer | Q38292875 | ||
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Q38364028 | ||
| Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials | Q40729813 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial | Q43658480 | ||
| PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage | Q86564392 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 2980-2987 | |
| P577 | publication date | 2016-06-27 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer | |
| P478 | volume | 34 |
| Q47637581 | A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. |
| Q91830069 | A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer |
| Q90541288 | A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel |
| Q37552085 | A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer |
| Q48191483 | Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab. |
| Q90326662 | An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer |
| Q37584395 | Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives |
| Q38765001 | Beyond platinum treatment for NSCLC: what does the future hold? |
| Q94526308 | Biomarkers of immune checkpoint inhibitor efficacy in cancer |
| Q37741143 | Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy |
| Q38840383 | Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. |
| Q56889030 | Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma |
| Q89910962 | Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection |
| Q93013655 | Cancer immunotherapy experience in the Integral Oncology Centre "Diana Laura Riojas de Colosio", Médica Sur Hospital |
| Q30275719 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. |
| Q47711273 | Cell death-based treatment of lung adenocarcinoma |
| Q50231313 | Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies |
| Q41722598 | Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer |
| Q47133911 | Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells |
| Q94552708 | Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer |
| Q99582797 | Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis |
| Q47727627 | Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature |
| Q53740080 | Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. |
| Q91599315 | Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer |
| Q90194707 | Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer |
| Q58614434 | Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis |
| Q92557086 | Correlation analysis of mRNA expression and prognosis of hOGG1 gene polymorphism in patients with non-small cell lung cancer |
| Q28076294 | Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment |
| Q33645595 | Current state of immunotherapy for non-small cell lung cancer |
| Q52690105 | Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. |
| Q58107449 | Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer |
| Q88698989 | Diminished but not dead: chemotherapy for the treatment of NSCLC |
| Q55375458 | Do immune checkpoint inhibitors need new studies methodology? |
| Q47688850 | Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab |
| Q98164819 | Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials |
| Q57034228 | Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316) |
| Q39441719 | Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. |
| Q50129978 | Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. |
| Q47131539 | Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis |
| Q47259728 | Excellent response to chemotherapy post immunotherapy |
| Q49240447 | Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma |
| Q47111652 | Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients |
| Q61814958 | F-FDG and C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study |
| Q55256789 | Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. |
| Q39388286 | First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. |
| Q28073759 | Focus on Nivolumab in NSCLC |
| Q64971959 | Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. |
| Q60104303 | Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors |
| Q92433697 | Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung |
| Q89767107 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas |
| Q49512731 | Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer |
| Q90334361 | Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis? |
| Q33645590 | Immune checkpoint blockade for hematologic malignancies: a review |
| Q91812593 | Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion |
| Q47563451 | Immune checkpoint inhibitors in advanced non-small cell lung cancer |
| Q92890675 | Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response |
| Q37589557 | Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know |
| Q47101155 | Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis |
| Q60936723 | Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis |
| Q64967034 | Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. |
| Q48131613 | Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. |
| Q38772744 | Immunogenomics: using genomics to personalize cancer immunotherapy. |
| Q38703148 | Immunotherapeutic Approaches to Biliary Cancer |
| Q38687631 | Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future |
| Q55503616 | Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. |
| Q58699431 | Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors? |
| Q55312983 | Immunotherapy in the Asiatic population: any differences from Caucasian population? |
| Q52624361 | Immunotherapy in treatment naïve advanced non-small cell lung cancer |
| Q38819349 | Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology |
| Q55438062 | Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. |
| Q47705923 | Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. |
| Q55438940 | Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. |
| Q90960156 | Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists |
| Q61799197 | L265P mutation and loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas |
| Q39160974 | LAG3 (CD223) as a cancer immunotherapy target |
| Q38670099 | Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies |
| Q64963588 | Liquid biopsy for lung cancer immunotherapy. |
| Q60044246 | Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer |
| Q49413036 | Locally advanced non-small cell lung cancer treatment: another step forward |
| Q88318229 | Lung cancer: First-line immunotherapy in lung cancer - taking the first step |
| Q90660460 | Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor |
| Q91906493 | M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer |
| Q92586096 | Making cold malignant pleural effusions hot: driving novel immunotherapies |
| Q39458112 | Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology. |
| Q49391681 | Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment |
| Q39007500 | New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. |
| Q41508440 | Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer |
| Q39118471 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. |
| Q64939605 | Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. |
| Q40289794 | Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial |
| Q38755931 | PD-1 and PD-L1 antibodies in cancer: current status and future directions |
| Q39033713 | PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? |
| Q47120629 | PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? |
| Q47422615 | PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer |
| Q36363579 | PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data |
| Q38774259 | PD-L1 testing, fit for routine evaluation? From a pathologist's point of view |
| Q90030532 | Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria |
| Q40346982 | Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial |
| Q42372526 | Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? |
| Q64116168 | Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment |
| Q89834907 | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study |
| Q57191808 | Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences |
| Q55311366 | Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. |
| Q61817209 | Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer |
| Q52729304 | Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations |
| Q52902960 | Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer |
| Q41339254 | Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review |
| Q50070316 | Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system |
| Q91651231 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors |
| Q53641678 | Raising the bar on first-line immunotherapy in lung cancer |
| Q28069323 | Recent Advances in Immunotherapy in Metastatic NSCLC |
| Q92106808 | Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing |
| Q38737954 | Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma |
| Q38870763 | Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. |
| Q93083934 | Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series |
| Q50746388 | Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. |
| Q55359370 | Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q42275107 | SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting |
| Q92093081 | SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells |
| Q89097028 | Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy |
| Q92685189 | Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations |
| Q55362771 | Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy. |
| Q94232616 | Single or combined immune checkpoint inhibitors compared to first‐line chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer |
| Q36305457 | Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
| Q47712161 | Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors |
| Q39103431 | Targeting ALK: Precision Medicine Takes on Drug Resistance |
| Q58783242 | Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer |
| Q58779547 | The Expanding Role of Radiosurgery for Brain Metastases |
| Q64030468 | The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies |
| Q53835314 | The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. |
| Q58561576 | The clinical role of the TME in solid cancer |
| Q38638860 | The evolutionary nature of the cancer immunotherapy revolution |
| Q93186621 | The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer |
| Q91520697 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy |
| Q33597192 | The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma |
| Q49795317 | The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective |
| Q38824489 | The next generation of immunotherapy: keeping lung cancer in check. |
| Q92463703 | The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy |
| Q38788124 | The safety of nivolumab for the treatment of advanced non-small cell lung cancer |
| Q50921394 | The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives |
| Q39172334 | Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy |
| Q90300273 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis |
| Q47393365 | Trial watch: Immune checkpoint blockers for cancer therapy |
| Q55401255 | Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. |
| Q50544077 | Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo |
| Q38604723 | Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors |
| Q38619196 | β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. |
Search more.